{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:47:11Z","timestamp":1790063231134,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T00:00:00Z","timestamp":1499817600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s10741-017-9637-0","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T17:53:41Z","timestamp":1499882021000},"page":"775-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-6586","authenticated-orcid":false,"given":"Hidekatsu","family":"Fukuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Wakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Ohte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,12]]},"reference":[{"key":"9637_CR1","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0735-1097(99)00118-7","volume":"33","author":"RS Vasan","year":"1999","unstructured":"Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D (1999) Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33:1948\u20131955","journal-title":"J Am Coll Cardiol"},{"key":"9637_CR2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251\u2013259","journal-title":"N Engl J Med"},{"key":"9637_CR3","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1253\/circj.CJ-09-0254","volume":"73","author":"M Tsuchihashi-Makaya","year":"2009","unstructured":"Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S et al (2009) Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73:1893\u20131900","journal-title":"Circ J"},{"key":"9637_CR4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362:777\u2013781","journal-title":"Lancet"},{"key":"9637_CR5","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456\u20132467","journal-title":"N Engl J Med"},{"key":"9637_CR6","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338\u20132345","journal-title":"Eur Heart J"},{"key":"9637_CR7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392","journal-title":"N Engl J Med"},{"key":"9637_CR8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","volume":"15","author":"K Yamamoto","year":"2013","unstructured":"Yamamoto K, Origasa H, Hori M (2013) Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15:110\u2013118","journal-title":"Eur J Heart Fail"},{"key":"9637_CR9","doi-asserted-by":"crossref","unstructured":"The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429\u20131435","DOI":"10.1056\/NEJM198706043162301"},{"key":"9637_CR10","doi-asserted-by":"crossref","unstructured":"The SOLVD investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293\u2013302","DOI":"10.1056\/NEJM199108013250501"},{"key":"9637_CR11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772\u2013776","journal-title":"Lancet"},{"key":"9637_CR12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pcad.2005.02.001","volume":"47","author":"K Hogg","year":"2005","unstructured":"Hogg K, McMurray J (2005) Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis 47:357\u2013366","journal-title":"Prog Cardiovasc Dis"},{"key":"9637_CR13","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","volume":"64","author":"RJ Mentz","year":"2014","unstructured":"Mentz RJ, Kelly JP, von Lueder TG et al (2014) Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64:2281\u20132293","journal-title":"J Am Coll Cardiol"},{"key":"9637_CR14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0002-8703(97)70123-6","volume":"134","author":"EF Philbin","year":"1997","unstructured":"Philbin EF, Rocco TA Jr (1997) Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 134:188\u2013195","journal-title":"Am Heart J"},{"key":"9637_CR15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9343(00)00601-X","volume":"109","author":"EF Philbin","year":"2000","unstructured":"Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL (2000) Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 109:605\u2013613","journal-title":"Am J Med"},{"key":"9637_CR16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1054\/jcaf.2001.26896","volume":"7","author":"KW Dauterman","year":"2001","unstructured":"Dauterman KW, Go AS, Rowell R, Gebretsadik T, Gettner S, Massie BM (2001) Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail 7:221\u2013228","journal-title":"J Card Fail"},{"key":"9637_CR17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1067\/mhj.2002.124058","volume":"144","author":"A Ahmed","year":"2002","unstructured":"Ahmed A, Roseman JM, Duxbury AS, Allman RM, DeLong JF (2002) Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J 144:365\u2013372","journal-title":"Am Heart J"},{"key":"9637_CR18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0002-9149(02)03173-9","volume":"91","author":"CA Sueta","year":"2003","unstructured":"Sueta CA, Russo A, Schenck A, Brown DW, Simpson RJ (2003) Effect of angiotensin-converting inhibitor or angiotensin receptor blocker on one-year survival in patients > or =65\u00a0years hospitalized with a left ventricular ejection fraction > or =50%. Am J Cardiol 91:363\u2013365","journal-title":"Am J Cardiol"},{"key":"9637_CR19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.104.519876","volume":"112","author":"H Fukuta","year":"2005","unstructured":"Fukuta H, Sane DC, Brucks S, Little WC (2005) Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112:357\u2013363","journal-title":"Circulation"},{"key":"9637_CR20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.12.022","volume":"150","author":"JD Chan","year":"2005","unstructured":"Chan JD, Rea TD, Smith NL et al (2005) Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). Am Heart J 150:464\u2013470","journal-title":"Am Heart J"},{"key":"9637_CR21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjcard.2007.08.050","volume":"101","author":"R Shah","year":"2008","unstructured":"Shah R, Wang Y, Foody JM (2008) Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients > or =65\u00a0years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol 101:217\u2013222","journal-title":"Am J Cardiol"},{"key":"9637_CR22","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.105.594952","volume":"115","author":"RB D\u2019Agostino Jr","year":"2007","unstructured":"D\u2019Agostino RB Jr (2007) Propensity scores in cardiovascular research. Circulation 115:2340\u20132343","journal-title":"Circulation"},{"key":"9637_CR23","doi-asserted-by":"crossref","unstructured":"Martens EP, Pestman WR, De, BA, Belitser SV, Klungel OH. Systematic differences in treatment effect estimates between propensity score methods and logistic regression. Int J Epidemiol 2008;37:1142\u20131147","DOI":"10.1093\/ije\/dyn079"},{"key":"9637_CR24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269 W64","journal-title":"Ann Intern Med"},{"key":"9637_CR25","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008\u20132012","journal-title":"JAMA"},{"key":"9637_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"9637_CR27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"9637_CR28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.amjcard.2007.10.026","volume":"101","author":"C Tribouilloy","year":"2008","unstructured":"Tribouilloy C, Rusinaru D, Leborgne L, Peltier M, Massy Z, Slama M (2008) Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol 101:639\u2013644","journal-title":"Am J Cardiol"},{"key":"9637_CR29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/eurjhf\/hfs101","volume":"14","author":"K Patel","year":"2012","unstructured":"Patel K, Fonarow GC, Kitzman DW et al (2012) Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail 14:1179\u20131188","journal-title":"Eur J Heart Fail"},{"key":"9637_CR30","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2012.14785","volume":"308","author":"LH Lund","year":"2012","unstructured":"Lund LH, Benson L, Dahlstrom U, Edner M (2012) Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308:2108\u20132117","journal-title":"JAMA"},{"key":"9637_CR31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.amjmed.2013.01.004","volume":"126","author":"M Mujib","year":"2013","unstructured":"Mujib M, Patel K, Fonarow GC et al (2013) Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med 126:401\u2013410","journal-title":"Am J Med"},{"key":"9637_CR32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cardfail.2005.09.001","volume":"12","author":"SL Grigorian","year":"2006","unstructured":"Grigorian SL, Roman AV, Ramos PM, Veloso PR, Bandin Dieguez MA, Gonzalez-Juanatey JR (2006) Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. J Card Fail 12:128\u2013133","journal-title":"J Card Fail"},{"key":"9637_CR33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10741-012-9329-8","volume":"18","author":"V Agarwal","year":"2013","unstructured":"Agarwal V, Briasoulis A, Messerli FH (2013) Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Fail Rev 18:429\u2013437","journal-title":"Heart Fail Rev"},{"key":"9637_CR34","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/00004872-200309000-00024","volume":"21","author":"Y Sakata","year":"2003","unstructured":"Sakata Y, Yamamoto K, Mano T et al (2003) Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrix. J Hypertens 21:1737\u20131745","journal-title":"J Hypertens"},{"key":"9637_CR35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00004872-200502000-00022","volume":"23","author":"K Yamamoto","year":"2005","unstructured":"Yamamoto K, Mano T, Yoshida J et al (2005) ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 23:393\u2013400","journal-title":"J Hypertens"},{"key":"9637_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","volume":"115","author":"AU Klingbeil","year":"2003","unstructured":"Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115:41\u201346","journal-title":"Am J Med"},{"key":"9637_CR37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/hc1202.105290","volume":"105","author":"MR Zile","year":"2002","unstructured":"Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 105:1503\u20131508","journal-title":"Circulation"},{"key":"9637_CR38","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1056\/NEJMcp022709","volume":"351","author":"GP Aurigemma","year":"2004","unstructured":"Aurigemma GP, Gaasch WH (2004) Clinical practice. Diastolic heart failure. N Engl J Med 351:1097\u20131105","journal-title":"N Engl J Med"},{"key":"9637_CR39","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMp048064","volume":"350","author":"MM Redfield","year":"2004","unstructured":"Redfield MM (2004) Understanding \u201cdiastolic\u201d heart failure. N Engl J Med 350:1930\u20131931","journal-title":"N Engl J Med"},{"key":"9637_CR40","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.ATV.0000160548.78317.29","volume":"25","author":"SJ Zieman","year":"2005","unstructured":"Zieman SJ, Melenovsky V, Kass DA (2005) Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25:932\u2013943","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9637_CR41","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke MF. Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance. J Am Coll Cardiol 2001;38:803\u2013805","DOI":"10.1016\/S0735-1097(01)01452-8"},{"key":"9637_CR42","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/01.RES.0000129254.25507.d6","volume":"94","author":"DA Kass","year":"2004","unstructured":"Kass DA, Bronzwaer JG, Paulus WJ (2004) What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 94:1533\u20131542","journal-title":"Circ Res"},{"key":"9637_CR43","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","volume":"101","author":"MG Sutton","year":"2000","unstructured":"Sutton MG, Sharpe N (2000) Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101:2981\u20132988","journal-title":"Circulation"},{"key":"9637_CR44","doi-asserted-by":"crossref","first-page":"e4059","DOI":"10.1097\/MD.0000000000004059","volume":"95","author":"S Chaugai","year":"2016","unstructured":"Chaugai S, Sherpa LY, Sepehry AA, Arima H, Wang DW (2016) Effect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation: a meta-analysis and systematic review of randomized controlled trials. Medicine (Baltimore) 95:e4059","journal-title":"Medicine (Baltimore)"},{"key":"9637_CR45","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.jacc.2006.01.060","volume":"47","author":"LG Olsson","year":"2006","unstructured":"Olsson LG, Swedberg K, Ducharme A et al (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47:1997\u20132004","journal-title":"J Am Coll Cardiol"},{"key":"9637_CR46","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2010.01.043","volume":"55","author":"MP Schneider","year":"2010","unstructured":"Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010) Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55:2299\u20132307","journal-title":"J Am Coll Cardiol"},{"key":"9637_CR47","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.jacc.2016.07.781","volume":"68","author":"WS Jones","year":"2016","unstructured":"Jones WS, Roe MT, Antman EM et al (2016) The changing landscape of randomized clinical trials in cardiovascular disease. J Am Coll Cardiol 68:1898\u20131907","journal-title":"J Am Coll Cardiol"},{"key":"9637_CR48","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1161\/01.CIR.0000144474.65922.AA","volume":"110","author":"SD Solomon","year":"2004","unstructured":"Solomon SD, Wang D, Finn P et al (2004) Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 110:2180\u20132183","journal-title":"Circulation"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-017-9637-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-017-9637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-017-9637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T02:38:12Z","timestamp":1507603092000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-017-9637-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,12]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["9637"],"URL":"https:\/\/doi.org\/10.1007\/s10741-017-9637-0","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,12]]}}}